Terms: = Bone cancer AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Prognosis
6 results:
1. Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.
Gaumond SI; Abdin R; Costoya J; Schally AV; Jimenez JJ
Oncotarget; 2024 Apr; 15():248-254. PubMed ID: 38588464
[TBL] [Abstract] [Full Text] [Related]
2. [Synchronous multicentric osteosarcoma: treatment and prognostic factor analysis].
Liu WF; Huang Z; Gong LH; Yang YK; Jin T; Deng ZP; Li Y; Hao L; Zhang Q; Ding Y; Niu XH
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(37):2897-2902. PubMed ID: 31607017
[No Abstract] [Full Text] [Related]
3. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean cancer Study of the Prostate risk classification.
Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
[TBL] [Abstract] [Full Text] [Related]
4. Peroxiredoxin 1 (PRDX1) Suppresses Progressions and Metastasis of Osteosarcoma and Fibrosarcoma of bone.
Wang Y; Liu M; Yang P; Peng H
Med Sci Monit; 2018 Jun; 24():4113-4120. PubMed ID: 29908016
[TBL] [Abstract] [Full Text] [Related]
5. [Preliminary study on the value of 99Tc(m)-HL91 imaging in predicting sensitivity to radiotherapy in patients with nasopharyngeal carcinoma].
Liu S; Xue Y; Zhang H; Liang JG; Lu XP; Liu XG; Chen SX; Jing NY
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):369-72. PubMed ID: 17892134
[TBL] [Abstract] [Full Text] [Related]
6. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson cancer Center experience from 1978 to 1998.
Kunschner LJ; Kuttesch J; Hess K; Yung WK
Neuro Oncol; 2001 Jul; 3(3):167-73. PubMed ID: 11465397
[TBL] [Abstract] [Full Text] [Related]
